Find out how we work with external companies and organisations.
See More >
Collaborating in more than 150 markets. By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com. These sections or websites are governed by their own Legal and Privacy Policies.
Janssen EMEA › ERLEADA® (apalutamide) Significantly Improved Overall Survival and Radiographic Progression-Free Survival in Patients with Metastatic HormoneSensitive Prostate Cancer
ERLEADA® (apalutamide) Significantly Improved Overall Survival and Radiographic Progression-Free Survival in Patients with Metastatic HormoneSensitive Prostate Cancer
ERLEADA® (apalutamide) Significantly Improved Overall Survival and Radiographic Progression-Free Survival in Patients with Metastatic HormoneSensitive Prostate Cancer
